About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Cancer Cells: Too Unstable For Fine Targeting? | Main | Avastin: Taking It Back »

August 16, 2010

Is Genzyme a Buyable Company At All?

Email This Entry

Posted by Derek

Word is now that Genzyme's manufacturing problems won't be solved for years, which has people wondering if Sanofi-Aventis (or anyone) will feel safe making a bid for them. That's the single biggest issue hanging over the company, and that's an awful lot of uncertainly to be taking on.

If so, it looks more and more like whoever set up this trade will end up doing just fine on it. . .

Comments (3) + TrackBacks (0) | Category: Business and Markets


1. Hap on August 16, 2010 12:46 PM writes...

Not at $80/share, I assume, and at a price S-A would pay, it would be too risky.

Maybe Genzyme is optimistic about their chances, or (more likely) their stockholders are hoping S-A will bail them out from the rest of their portfolios' losses. Good luck with that.

Permalink to Comment

2. Mark on August 16, 2010 1:00 PM writes...

Actually, I think it's the perfect time for Sanofi to buy the company:

1) The manufacturing problems are depressing the price of the stock. Even with the premium paid, you're getting a pretty good deal. Combine that with the current investors who are thinking "Let's see, take $80/share now or let the current management try and get the share price back up." It's a quick way out of the investment.

2) The FDA has already laid the smack-down on Genzyme. All Sanofi has to do is make sure it CAN meet the demands of the FDA consent decree. Basically you have a problem, but the solution is laid out in front of you, you just have to figure out whether or not you can do it. The FDA basically did a good chunk of the due diligence already!

3) If there is one thing that big pharma is good at it's paperwork. In the case of Genzyme, that's exactly what they need to fix their manufacturing problems; a clear, methodical QA system with plenty of checks and balances. Plus, Sanofi has the resources ($$$) to throw at fixing these problems once and for all. Genzyme says it will take years to fix the problem, but maybe Sanofi is thinking "We can fix this in two!".

I think Sanofi looks at Genzyme right now like an old rusty 68 1/2 Mustang. The current owners are motivated to sell and nobody else wants to touch it.


Permalink to Comment

3. Anon 1 on August 16, 2010 2:49 PM writes...

So, it looks like their stock price should take a tumble.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry